CA2311679C - Utilisation d'une proteine soluble humaine de recombinaison cd40 afin d'inhiber une reponse immune in vivo - Google Patents

Utilisation d'une proteine soluble humaine de recombinaison cd40 afin d'inhiber une reponse immune in vivo Download PDF

Info

Publication number
CA2311679C
CA2311679C CA2311679A CA2311679A CA2311679C CA 2311679 C CA2311679 C CA 2311679C CA 2311679 A CA2311679 A CA 2311679A CA 2311679 A CA2311679 A CA 2311679A CA 2311679 C CA2311679 C CA 2311679C
Authority
CA
Canada
Prior art keywords
hla
mice
soluble recombinant
recombinant human
cd40l
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2311679A
Other languages
English (en)
Other versions
CA2311679A1 (fr
Inventor
Alan H. Lazarus
Andrew R. Crow
John Freedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canadian Blood Services
Original Assignee
Canadian Blood Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002223225A external-priority patent/CA2223225A1/fr
Application filed by Canadian Blood Services filed Critical Canadian Blood Services
Priority to CA2311679A priority Critical patent/CA2311679C/fr
Publication of CA2311679A1 publication Critical patent/CA2311679A1/fr
Application granted granted Critical
Publication of CA2311679C publication Critical patent/CA2311679C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un procédé servant à inhiber une réponse immune in vivo et l'utilisation d'une CD40L soluble humaine de recombinaison ou d'une séquence de ladite CD40L soluble humaine de recombinaison contenant le site de fixation actif avec CD40 afin d'inhiber une réponse immune. Elle concerne également un modèle de souris d'allo-immunisation humaine servant à tester les effets in vivo d'une immunothérapie ou d'une inhibition de la réponse humaine aux anticorps.
CA2311679A 1997-11-28 1998-11-27 Utilisation d'une proteine soluble humaine de recombinaison cd40 afin d'inhiber une reponse immune in vivo Expired - Fee Related CA2311679C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2311679A CA2311679C (fr) 1997-11-28 1998-11-27 Utilisation d'une proteine soluble humaine de recombinaison cd40 afin d'inhiber une reponse immune in vivo

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA002223225A CA2223225A1 (fr) 1997-11-28 1997-11-28 Methode d'inhibition de la reaction immunitaire in vivo
CA2,223,225 1997-11-28
PCT/CA1998/001105 WO1999027948A2 (fr) 1997-11-28 1998-11-27 UTILISATION D'UNE PROTEINE SOLUBLE HUMAINE DE RECOMBINAISON CD40 AFIN D'INHIBER UNE REPONSE IMMUNE $i(IN VIVO)
CA2311679A CA2311679C (fr) 1997-11-28 1998-11-27 Utilisation d'une proteine soluble humaine de recombinaison cd40 afin d'inhiber une reponse immune in vivo

Publications (2)

Publication Number Publication Date
CA2311679A1 CA2311679A1 (fr) 1999-06-10
CA2311679C true CA2311679C (fr) 2011-02-15

Family

ID=25679881

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2311679A Expired - Fee Related CA2311679C (fr) 1997-11-28 1998-11-27 Utilisation d'une proteine soluble humaine de recombinaison cd40 afin d'inhiber une reponse immune in vivo

Country Status (1)

Country Link
CA (1) CA2311679C (fr)

Also Published As

Publication number Publication date
CA2311679A1 (fr) 1999-06-10

Similar Documents

Publication Publication Date Title
Qin et al. Induction of tolerance in peripheral T cells with monoclonal antibodies
Cobbold et al. The induction of skin graft tolerance in major histocompatibility complex‐mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti‐CD4 and anti‐CD8 antibodies
US6312692B1 (en) Method of treating graft-versus-host disease with anti-GP39 antibodies and bone marrow cells
ES2237757T3 (es) Metodos para inducir la tolerancia de celulas t a un injerto de tejido u organo.
Benjamin et al. Mechanisms of monoclonal antibody‐facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA‐1) molecules in self‐non‐self discrimination
US5869049A (en) Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
US6056956A (en) Non-depleting anti-CD4 monoclonal antibodies and tolerance induction
US7087573B1 (en) Methods of inhibiting platelet anti-HLA alloimmune antibody responses with soluble 18 KDa CD40L
KR0183029B1 (ko) 내성을 유도하기 위한 모노클론 항체류
JPH11509558A (ja) 免疫反応を惹起するための、多数エピトープ含有抗原の再構成法および組成物
CA2311679C (fr) Utilisation d'une proteine soluble humaine de recombinaison cd40 afin d'inhiber une reponse immune in vivo
Lazarus et al. Induction of a secondary human anti‐HLA alloimmune response in severe combined immunodeficient mice engrafted with human lymphocytes
WO1999047166A1 (fr) FRAGMENTS IMMUNOMODULATEURS DE GLOBULINES ANTILYMPHOCYTAIRES POLYCLONALES (ALGs) ET UTILISATIONS ASSOCIEES
Miller Immunological tolerance
WO2001000679A2 (fr) Procedes permettant d'induire une tolerance des cellules t a une greffe de tissu ou d'organe
Yamaguchi et al. Difficulties in obtaining monoclonal antibodies to subsets of human leukocytes, using neonatal tolerance induction in mice
Wenk et al. Anti-Human CD4 Induces Peripheral
Cobbold Cambridge zyxwvutsrqponmlkjihgfedcb
Graça Mechanisms of peripheral tolerance in transplantation
Litzinger Tracking B and T lymphocytes in vivo during peptide-IgG gene-transferred tolerance induction
Contreras Characterization of human T cell clones specific to the 27 kDa protein of Plasmodium falciparum gametocyte
King Chimerism and NK cell activity across a major histocompatibility complex class I disparity
Burns The role of memory B cells and alloantibodies in preventing transplantation tolerance
Ahmiedat Induction of Transplantation Tolerance Using Monoclonal Antibodies to CD4: Experimental Studies Using a Rat Heterotopic Cardiac Allograft Model
Taylor Making mice more human: The development of a humanised mouse vaccination model to study human antibody responses against intestinal helminths

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20171127